PhenoMx

PhenoMx, established in 2017 by founders Mark Punyanitya, Zachary Rapp, and Girish Srinivasan, operates as a medical image analysis platform developer. The New York City-based company is centered on commercializing a “Personalized Digital Physical Examination.”

This service utilizes non-invasive MRI scans to measure vital organs and tissues throughout the body. The core of PhenoMx's offering is an imaging platform designed for quantitative phenotyping of the entire body. The software can be integrated into MRI scanners, enabling automated processing and the generation of reports for physicians. This technology aims to monitor and measure organ-specific, regional, or whole-body phenotypic changes over time. The ultimate goal is to provide direct and quantitative measurements that help in predicting disease risks. By offering a detailed view of an individual's internal health, the company serves the precision medicine and personalized wellness markets, with a focus on increasing longevity.

The company's intellectual property includes patents for methods and apparatuses related to multi-modality medical image analysis for diagnosing brain diseases and for providing information for the diagnosis of lymph node metastasis in thyroid cancer.

Keywords: medical imaging, MRI analysis, whole-body scanning, quantitative phenotyping, precision medicine, personalized wellness, preventative healthcare, disease risk prediction, organ health monitoring, medical diagnostics, HealthTech, digital physical examination, non-invasive diagnostics, longevity, Mark Punyanitya, Zachary Rapp, Girish Srinivasan, medical image analysis platform, automated medical reporting